House panel supports 12-year exclusivity for biotech drugs

08/3/2009 | Wall Street Journal, The

The House Energy and Commerce Committee voted 47-11 to approve a measure that would give 12 years of market protection to brand-name biotech medicines. The amendment "takes a balanced approach between innovation, cost savings for consumers and safety," said a spokeswoman for Rep. Jay Inslee, D-Wash., one of the sponsors of the bill.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL